Aytu Biopharma (AYTU) Revenue (2013 - 2026)

Aytu Biopharma (AYTU) has 14 years of Revenue data on file, last reported at $12.4 million in Q1 2026.

• On a quarterly basis, Revenue fell 32.74% year-over-year to $12.4 million in Q1 2026; TTM through Mar 2026 was $56.6 million, a 14.04% decrease from a year earlier, with the FY2025 full-year figure at $66.4 million, up 1.84% from the prior year.
• Revenue for Q1 2026 stood at $12.4 million, down from $15.2 million in the prior quarter.
• Over the last five years, Revenue for AYTU reached as high as $30.7 million in Q2 2023 and fell as low as $12.4 million in Q1 2026.
• Historically, Revenue has averaged $19.5 million across 5 years, with a median of $17.8 million in 2023.
• Across the five-year window, Revenue tumbled 52.52% in 2024 and surged 31.57% in 2025, its largest moves.
• Year by year, Revenue stood at $26.3 million in 2022, then retreated by 28.66% to $18.7 million in 2023, then decreased by 13.48% to $16.2 million in 2024, then decreased by 6.51% to $15.2 million in 2025, then slipped by 18.16% to $12.4 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $12.4 million in Q1 2026, $15.2 million in Q4 2025, and $13.9 million in Q3 2025.